Aclarion, Inc. ACON 深 沪
已收盘 07-02 16:00:00 美东时间
3.09
+0.070
+2.32%
华盛通- 最 高3.11
- 今 开3.045
- 成交量 2.13万股
- 最 低 3.0201
- 昨 收 3.02
- 总市值 760.84万
- 52周最高 12.03
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 2.3401
- 委 比 -26.37%
- 总股本 246.23万
- 历史最高 586116.00
- 量 比 0.48
- 振 幅 2.98%
- 历史最低 2.3401
- 每 手 1
- 风险率 2.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion Launches Market Access Program In Partnership With PRIA Healthcare
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.Program aims to follow successful reimbursement wins in the UK that are translating
06-09 19:04
Aclarion Board Reviews Echo Lake's Unsolicited Public Proposal And Unanimously Determined To Reject It
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help
06-08 19:13
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
Echo Lake Capital Offers To Acquire Aclarion At $4.00/Share And Contingent Value Right Representing Right For Stockholders To Receive 80% Of Net Proceeds From Nociscan Sale.
Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse takeoverStock price
05-28 20:04
Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate
Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.55) by 13.55 percent. This is a 85.62 percent increase over losses of $(9.32) per share from the same
05-14 05:50
Aclarion Establishes Second Commercial Agreement With Weill Cornell Medicine; Deal Brings Nociscan To Weill Cornell Medicine And Och Spine At Newyork-Presbyterian/Weill Cornell Medical Center
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through
05-05 18:11
Aclarion Announces $2.5M Buyback Plan
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its
04-22 20:31
Aclarion Secures U.S. Patent Covering Machine Learning–Based Platform For Analyzing Magnetic Resonance Spectroscopy Data
Patent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and pending patents
04-16 18:49
Aclarion Signs Commercial Agreement With Weill Cornell Medicine Over Access For Nociscan To Weill Cornell, Och Spine
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help
04-08 20:07
美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
